Carlos Porras

Carlos Porras

Auto-generated profile, based on publicly available information

Carlos Porras

Unidad de Gestión Clínica del Corazón y Patología Cardiovascular, Servicio de Cirugía Cardíaca, Hospital Universitario Virgen de la Victoria, Málaga, España

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
JCJuan Caballero-Borrego
Juan Caballero-Borrego
JDJuan Jose Gomez Doblas
Juan Jose Gomez Doblas
FCFernando Cabrera-Bueno
Fernando Cabrera-Bueno
JGJosé Manuel García-Pinilla
José Manuel García-Pinilla
JMJosé María Melero
José María Melero
EGEduardo De Teresa Galván
Eduardo De Teresa Galván
In order to improve the prognosis, repair of severe mitral regurgitation should be undertaken at the same time as aortic valve replacement in patients with severe aortic valve stenosis. However, mitral regurgitation may be secondary to pressure overload or ventricular dysfunction and improve after surgery. To assess the incidence of non-severe functional mitral regurgitation before and after isolated aortic valve replacement and determine its influence on the postoperative course. The clinical and surgical characteristics were compared in a cohort of 577 consecutive patients who underwent isolated aortic valve replacement. The mean age was 68.4+/-9.2 years (44% women). Non-severe functional mitral valve regurgitation was detected prior to surgery in 26.5% of the patients. These patients were older (p=0.009), more often had ventricular dysfunction (p=0.005) and pulmonary hypertension (0.002), and had been admitted more frequently for heart failure (0.002), with fewer of them conserving sinus rhythm (p<0.001). Additionally, the pre-surgery existence of mitral regurgitation was associated with greater morbidity and mortality (10.5% vs 5.6%; p=0.025). The mitral regurgitation disappeared or improved prior to hospital discharge in 56.2% and 15.6%, respectively. Independent factors predicting this improvement were the presence of coronary lesions (OR 3.7, p=0.038), and the absence of diabetes (OR 0.28, p=0.011) and pulmonary hypertension (0.33, p=0.046). The presence of intermediate degree mitral regurgitation in patients undergoing isolated aortic valve replacement increases morbidity and mortality. However, a high percentage of those who do survive experience disappearance or improvement of the mitral regurgitation.

22 January 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
VBVictor M. Becerra-Munoz
Victor M. Becerra-Munoz
JDJuan Jose Gomez Doblas
Juan Jose Gomez Doblas
CPCarlos Porras-Martín
Carlos Porras-Martín
MSMiguel Such-Martínez
Miguel Such-Martínez
MCMaría Generosa Crespo-Leiro
María Generosa Crespo-Leiro
FCFernando Cabrera-Bueno
Fernando Cabrera-Bueno
Marfan syndrome (MFS) is a disorder of autosomal dominant inheritance, in which aortic root dilation is the main cause of morbidity and mortality. Fibrillin-1 (FBN-1) gene mutations are found in more than 90% of MFS cases. The aim of our study was to summarise variants in FBN-1 and establish the genotype-phenotype correlation, with particular interest in the onset of aortic events, in a broad population of patients with an initial clinical suspicion of MFS. This single centre prospective cohort study included all patients presenting variants in the FBN-1 gene who visited a Hereditary Aortopathy clinic between September 2010 and October 2016. The study included 90 patients with FBN-1 variants corresponding to 58 non-interrelated families. Of the 57 FBN-1 variants found, 25 (43.9%) had previously been described, 23 of which had been identified as associated with MFS, while the the remainder are described for the first time. For 84 patients (93.3%), it was possible to give a definite diagnosis of Marfan syndrome in accordance with Ghent criteria. 44 of them had missense mutations, 6 of whom had suffered an aortic event (with either prophylactic surgery for aneurysm or dissection), whereas 20 of the 35 patients with truncating mutations had suffered an event (13.6% vs. 57.1%, p < 0.001). These events tended to occur at earlier ages in patients with truncating compared to those with missense mutations, although not significantly (41.33 ± 3.77 vs. 37.5 ± 9.62 years, p = 0.162). Patients with MFS and truncating variants in FBN-1 presented a higher proportion of aortic events, compared to a more benign course in patients with missense mutations. Genetic findings could, therefore, have importance not only in the diagnosis, but also in risk stratification and clinical management of patients with suspected MFS.

1 June 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
FHFrederiek de Heer
Frederiek de Heer
JKJolanda Kluin
Jolanda Kluin
GEGebrine Elkhoury
Gebrine Elkhoury
GJGuillaume Jondeau
Guillaume Jondeau
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
KLKatie Leavitt
Katie Leavitt

19 August 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
IMInmaculada Moreno
Inmaculada Moreno
LPLuis Miguel Pérez-Belmonte
Luis Miguel Pérez-Belmonte
MMManuel Macias-Gonzalez
Manuel Macias-Gonzalez
MMMaría José Mataró
María José Mataró
DCDaniel Castellano-Castillo
Daniel Castellano-Castillo
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
Although recent studies indicate that epicardial adipose tissue expresses brown fat-like genes, such as PGC1α, UCP1 and PRDM16, the association of these genes with type 2 diabetes mellitus (DM2) in coronary artery disease (CAD) remains unknown. PGC1α, UCP1, and PRDM16 mRNAs expression levels were measured by real-time PCR in epicardial and thoracic subcutaneous adipose tissue from 44 CAD patients (22 with DM2 [CAD-DM2] and 22 without DM2 [CAD-NDM2]) and 23 non-CAD patients (NCAD). The CAD-DM2 patients had significantly lower PGC1α and UCP1 expression in epicardial adipose tissue than the CAD-NDM2 and NCAD patients. However, PGC1α and UCP1 mRNA trended upward in subcutaneous adipose tissue from CAD-DM2 patients. At multiple regression analysis, age, body mass index, left ventricular ejection fraction, UCP1 expression of epicardial adipose tissue and diabetes came out to be independent predictors of PGC1α levels. Epicardial adipose tissue PGC1α expression was dependent on the number of injured coronary arteries and logistic regression analysis showed that PGC1α expression in epicardial adipose tissue could exert a protective effect against coronary lesions. DM2 is associated with decreased expression of PGC1α and UCP1 mRNA in epicardial adipose tissue of patients with CAD, likely reflecting a loss of brown-like fat features. Decreased expression of PGC1α in human epicardial adipose tissue is associated with higher prevalence of coronary lesions.

1 October 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
JRJuan Robledo-Carmona
Juan Robledo-Carmona
IRIsabel Rodríguez-Bailón
Isabel Rodríguez-Bailón
FCFernando Carrasco-Chinchilla
Fernando Carrasco-Chinchilla
BFBorja Fernández
Borja Fernández
MJManuel Jiménez-Navarro
Manuel Jiménez-Navarro
ETEduardo De Teresa-Galván
Eduardo De Teresa-Galván

11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDominic Henn
Dominic Henn
DBDoris Bandner-Risch
Doris Bandner-Risch
HPHilja Perttunen
Hilja Perttunen
WSWolfram Schmied
Wolfram Schmied
CPCarlos Porras
Carlos Porras
HSHans-Joachim Schäfers
Hans-Joachim Schäfers
Hypertension and congenital aortic valve malformations are frequent causes of ascending aortic aneurysms. The molecular mechanisms of aneurysm formation under these circumstances are not well understood. Reference genes for gene activity studies in aortic tissue that are not influenced by aortic valve morphology and its hemodynamic consequences, aortic dilatation, hypertension, or antihypertensive medication are not available so far. This study determines genes in ascending aortic tissue that are independent of these parameters. Tissue specimens from dilated and undilated ascending aortas were obtained from 60 patients (age ≤70 years) with different morphologies of the aortic valve (tricuspid undilated n = 24, dilated n = 11; bicuspid undilated n = 6, dilated n = 15; unicuspid dilated n = 4). Of the studied individuals, 36 had hypertension, and 31 received ACE inhibitors or AT1 receptor antagonists. The specimens were obtained intraoperatively from the wall of the ascending aorta. We analyzed the expression levels of 32 candidate reference genes by quantitative RT-PCR (RT-qPCR). Differential expression levels were assessed by parametric statistics. The expression analysis of these 32 genes by RT-qPCR showed that EIF2B1, ELF1, and PPIA remained constant in their expression levels in the different specimen groups, thus being insensitive to aortic valve morphology, aortic dilatation, hypertension, and medication with ACE inhibitors or AT1 receptor antagonists. Unlike many other commonly used reference genes, the genes EIF2B1, ELF1, and PPIA are neither confounded by aortic comorbidities nor by antihypertensive medication and therefore are most suitable for gene expression analysis of ascending aortic tissue.